Bridging the treatment gap in infant medulloblastoma: molecularly informed outcomes of a globally feasible regimen

• Published in: Neuro-oncology (Charlottesville, Va.) Vol. 22; no. 12; pp. 1873 - 1881
• Main Authors: Baroni, Lorena V, Sampor, Claudia, Gonzalez, Adriana, Lubieniecki, Fabiana, Lamas, Gabriela, Rugilo, Carlos, Bartels, Ute, Heled, Ayala, Smith, Kyle S, Northcott, Paul A, Bouffet, Eric, Alderete, Daniel, Ramaswamy, Vijay
• Format: Journal Article
• Language: English
• Published: US Oxford University Press 18.12.2020
• Subjects: Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Argentina; Cerebellar Neoplasms - drug therapy; Child, Preschool; Cranial Irradiation; Female; Hedgehog Proteins - genetics; Humans; Infant; Male; Medulloblastoma - drug therapy; Pediatric Neuro-Oncology; Retrospective Studies; Argentina; brain tumor; SHH; infant; medulloblastoma; radiation
• ISSN: 1522-8517; 1523-5866
• DOI: 10.1093/neuonc/noaa122

Abstract Background Infant medulloblastoma represents an enormous challenge in neuro-oncology, due to their simultaneous high-risk of recurrence and high risk of severe neurodevelopmental sequelae with craniospinal irradiation. Currently infant medulloblastoma are treated with intensified protocols, either comprising intraventricular methotrexate or autologous transplant, both of which carry significant morbidity and are not feasible in the majority of the world. We sought to evaluate the molecular predictors of outcome in a cohort of infants homogeneously treated with induction chemotherapy, focal radiation and maintenance chemotherapy. Methods In a retrospective analysis, 29 young children treated with a craniospinal irradiation sparing strategy from Hospital Garrahan in Buenos Aires were profiled using Illumina HumanMethylationEPIC arrays, and correlated with survival. Results Twenty-nine children (range, 0.3–4.6 y) were identified, comprising 17 sonic hedgehog (SHH), 10 Group 3/4, and 2 non-medulloblastomas. Progression-free survival (PFS) across the entire cohort was 0.704 (95% CI: 0.551–0.899). Analysis by t-distributed stochastic neighbor embedding revealed 3 predominant groups, SHHβ, SHHγ, and Group 3. Survival by subtype was highly prognostic with SHHγ having an excellent 5-year PFS of 100% (95% CI: 0.633–1) and SHHβ having a PFS of 0.56 (95% CI: 0.42–1). Group 3 had a PFS of 0.50 (95% CI: 0.25–1). Assessment of neurocognitive outcome was performed in 11 patients; the majority of survivors fell within the low average to mild intellectual disability, with a median IQ of 73.5. Conclusions We report a globally feasible and effective strategy avoiding craniospinal radiation in the treatment of infant medulloblastoma, including a robust molecular correlation along with neurocognitive outcomes.